Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients
Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients
复制标题
DOI：
10.18632/oncotarget.18527
复制
发表时间：
2017-10-06
期刊：
影响因子：
--
通讯作者：
Masini, Carla
中科院分区：
文献类型：
--
作者：
Farolfi, Alberto;Silimbani, Paolo;Masini, Carla
我们对静脉(IV)和皮下(SC)曲妥珠单抗治疗早期乳腺癌(EBC)进行了经济学评价。利用2014年在我所接受曲妥珠单抗辅助治疗的患者的数据，研究了三种不同的治疗方案：1)曲妥珠单抗静脉注射，2)曲妥珠单抗SC，3)化疗期间静脉注射曲妥珠单抗，然后SC曲妥珠单抗。我们的队列包括114名患者，平均体重为63.75公斤。方案2是最节省时间的治疗方案，与方案1相比，准备时间减少了71.7%，主持时间减少了89.3%。考虑全部成本，方案1的每个患者/年的平均成本为(原文如此)14,233+/-8,698，方案2(原文如此)14,272+/-8,312，(原文如此)14,535+/-8,646(p=0.959)。当平均体重为65.2公斤时，方案2的平均成本低于方案1。方案2被证明是一个有价值的节省时间和成本的选择。应该考虑从静脉注射曲妥珠单抗转向SC曲妥珠单抗，特别是在能力有限的肿瘤科。
We conducted an economic evaluation of intravenous (IV) vs subcutaneous (SC) trastuzumab for the treatment of patients with early breast cancer (EBC). Data of patients receiving adjuvant IV trastuzumab at our institute in 2014 were used to study three different treatment scenarios: 1) IV trastuzumab, 2) SC trastuzumab, and 3) IV trastuzumab during chemotherapy followed by SC trastuzumab. Our cohort included 114 patients with a median weight of 63.75 kg. Scenario 2 was the most time-saving treatment, with 71.7% reduction in preparation time and 89.3% reduction in chair time compared to scenario 1. Considering full costs, the mean costs per patient/year were (sic) 14,233 +/- 8,698 for scenario 1, (sic) 14,272 +/- 8,312 for scenario 2, and (sic) 14,535 +/- 8,646 for scenario 3 (p = 0.959). When mean body weight was > 65.2 kg, the mean cost was lower in scenario 2 than in scenario 1. Scenario 2 proved a valuable time-saving and cost-saving option. A shift from IV to SC trastuzumab should be considered, especially in capacity-constrained oncology departments.